Jul 20, 2022 8:20pm EDT Virax Biolabs Group Limited Announces Pricing of $6.75 Million Initial Public Offering
May 09, 2022 9:01am EDT Virax Biolabs Receives Ethical Approval for its Virax Immune COVID-19 Analytical Performance Study from the SBEBO Foundation for the Assessment of Ethics of Biomedical Research
Apr 28, 2022 8:00am EDT Virax Biolabs Announces the Appointment of Jason D. Davis as Chief Financial Officer
